AMN Healthcare Announces Second Quarter 2025 Results
Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30
What is the current analyst consensus on the stock after the release—upgrades, downgrades, or rating changes?
What was the immediate market reaction (price movement, volume) to the release and how does that compare to typical earnings reactions for AMN?
Did the earnings release mention any regulatory or policy changes that may affect revenue or margins?
22 days ago